

# Nick Andrews

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8171680/publications.pdf>

Version: 2024-02-01

57  
papers

8,700  
citations

196777

29  
h-index

169272

56  
g-index

58  
all docs

58  
docs citations

58  
times ranked

11268  
citing authors

#	ARTICLE	IF	CITATIONS
1	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501
2	Impact of an accelerated measles-mumps-rubella (MMR) vaccine schedule on vaccine coverage: An ecological study among London children, 2012â€“2018. <i>Vaccine</i> , 2022, 40, 444-449.	1.7	7
3	Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. <i>Journal of Infectious Diseases</i> , 2022, 226, 808-811.	1.9	7
4	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546.	13.9	1,709
5	Effectiveness of BNT162b2 against COVID-19 in adolescents. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 581-583.	4.6	52
6	Characteristics associated with COVID-19 vaccine uptake among adults aged 50 years and above in England (8 December 2020â€“17 May 2021): a population-level observational study. <i>BMJ Open</i> , 2022, 12, e055278.	0.8	18
7	Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. <i>Journal of Infection</i> , 2022, 84, 814-824.	1.7	8
8	Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. <i>Lancet</i> , The, 2022, 399, 1303-1312.	6.3	889
9	Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021. <i>Vaccine</i> , 2022, 40, 4283-4291.	1.7	3
10	Summary of evidence to reduce the two-dose infant priming schedule to a single dose of the 13-valent pneumococcal conjugate vaccine in the national immunisation programme in the UK. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e93-e102.	4.6	7
11	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24341.	1.2	22
12	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10
13	Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes. <i>Vaccine</i> , 2021, 39, 1997-2004.	1.7	10
14	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
15	Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillainâ€“BarrÃ© Syndrome and Narcolepsy. <i>CNS Drugs</i> , 2020, 34, 1-8.	2.7	21
16	End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. <i>Vaccine</i> , 2020, 38, 489-497.	1.7	38
17	Protection provided by influenza vaccine against influenza-related hospitalisation in â‰¥65 year olds: Early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018/19. <i>Vaccine</i> , 2020, 38, 173-179.	1.7	17
18	Effectiveness of influenza vaccine in children in preventing influenza associated hospitalisation, 2018/19, England. <i>Vaccine</i> , 2020, 38, 158-164.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Delivering prenatal pertussis vaccine through maternity services in England: What is the impact on vaccine coverage?. <i>Vaccine</i> , 2020, 38, 5332-5336.	1.7	7
20	Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study. <i>BMJ Open</i> , 2020, 10, e037458.	0.8	8
21	Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing. <i>Vaccine</i> , 2020, 38, 7834-7841.	1.7	0
22	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1034-1042.	4.6	493
23	The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis. <i>Vaccine</i> , 2020, 38, 4935-4939.	1.7	14
24	Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: An ecological study. <i>Vaccine</i> , 2020, 38, 4816-4819.	1.7	6
25	Response to Letter to the editor by Signe SÃrup re: The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England. <i>Vaccine</i> , 2020, 38, 2116.	1.7	1
26	Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. <i>New England Journal of Medicine</i> , 2020, 382, 309-317.	13.9	154
27	Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e18606.	1.2	66
28	The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England. <i>Vaccine</i> , 2019, 37, 5211-5217.	1.7	11
29	Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018. <i>Vaccine</i> , 2019, 37, 4491-4498.	1.7	38
30	Serocorrelates of protection against infant group B streptococcus disease. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e162-e171.	4.6	46
31	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. <i>Vaccine</i> , 2019, 37, 3190-3198.	1.7	35
32	What school-level and area-level factors influenced HPV and MenACWY vaccine coverage in England in 2016/2017? An ecological study. <i>BMJ Open</i> , 2019, 9, e029087.	0.8	13
33	Serological surveillance of influenza in an English sentinel network: pilot study protocol. <i>BMJ Open</i> , 2019, 9, e024285.	0.8	23
34	Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study. <i>Health Technology Assessment</i> , 2019, 23, 1-40.	1.3	3
35	Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. <i>Lancet Public Health</i> , The, 2018, 3, e82-e90.	4.7	57
36	Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. <i>BMC Medicine</i> , 2018, 16, 13.	2.3	76

#	ARTICLE	IF	CITATIONS
37	Inequalities in childhood vaccination timing and completion in London. <i>Vaccine</i> , 2018, 36, 6726-6735.	1.7	31
38	Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. <i>PLoS ONE</i> , 2018, 13, e0195799.	1.1	80
39	Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17. <i>Eurosurveillance</i> , 2018, 23, .	3.9	19
40	No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. <i>Vaccine</i> , 2017, 35, 1729-1732.	1.7	52
41	Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006–2014. <i>Clinical Infectious Diseases</i> , 2017, 65, 1191-1198.	2.9	32
42	Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. <i>Eurosurveillance</i> , 2017, 22, .	3.9	30
43	Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. <i>Eurosurveillance</i> , 2016, 21, .	3.9	103
44	A Case-Control Study to Estimate the Effectiveness of Maternal Pertussis Vaccination in Protecting Newborn Infants in England and Wales, 2012-2013. <i>Clinical Infectious Diseases</i> , 2015, 60, 333-337.	2.9	328
45	Phased introduction of a universal childhood influenza vaccination programme in England: population-level factors predicting variation in national uptake during the first year, 2013/14. <i>Vaccine</i> , 2015, 33, 2620-2628.	1.7	26
46	Guillain-Barré Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe. <i>PLoS ONE</i> , 2014, 9, e82222.	1.1	53
47	Childhood vaccination coverage by ethnicity within London between 2006/2007 and 2010/2011. <i>Archives of Disease in Childhood</i> , 2014, 99, 348-353.	1.0	26
48	Effectiveness of maternal pertussis vaccination in England: an observational study. <i>Lancet</i> , The, 2014, 384, 1521-1528.	6.3	593
49	Effectiveness of trivalent and pandemic influenza vaccines in England and Wales 2008–2010: Results from a cohort study in general practice. <i>Vaccine</i> , 2012, 30, 1371-1378.	1.7	27
50	Accelerating Control of Pertussis in England and Wales. <i>Emerging Infectious Diseases</i> , 2012, 18, 38-47.	2.0	74
51	Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales. <i>PLoS ONE</i> , 2011, 6, e28435.	1.1	56
52	Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. <i>Vaccine</i> , 2010, 28, 7215-7220.	1.7	30
53	No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine. <i>Vaccine</i> , 2009, 27, 1422-1425.	1.7	38
54	Investigation of the Temporal Association of Guillain-Barre Syndrome With Influenza Vaccine and Influenza-like Illness Using the United Kingdom General Practice Research Database. <i>American Journal of Epidemiology</i> , 2008, 169, 382-388.	1.6	159

#	ARTICLE	IF	CITATIONS
55	No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Archives of Disease in Childhood, 2007, 92, 887-889.	1.0	33
56	Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Lancet, The, 2003, 362, 449-450.	6.3	62
57	Bacterial infections, immune overload, and MMR vaccine. Archives of Disease in Childhood, 2003, 88, 222-223.	1.0	41